- NeuroQuant® ARIA
Accurate segmentation, quantification, and longitudinal tracking of lesions to support ARIA treatment
NeuroQuant® 5.0 enables precise segmentation and quantification of T2*GRE, SWI, and FLAIR lesions, supporting ARIA-E and ARIA-H surveillance and grading. This advanced functionality facilitates longitudinal tracking of lesion dynamics for patients receiving anti-amyloid therapies.
AI-Assisted Monitoring for Alzheimer's Disease Patients on Anti-Amyloid Immunotherapies
NeuroQuant ARIA offers comprehensive FLAIR lesion segmentation and quantification, enabling physicians to accurately monitor lesion dynamics—including lesion count, max diameter, and volume—in patients receiving anti-amyloid therapies, which supports informed decision-making and monitoring over time.
Benefits
Quantitative lesion detection
Detailed segmentation and quantification of lesions in FLAIR and T2*GRE/SWI
OEM protocol standardization
To ensure reproducible outcomes and accuracy over time
Longitudinal disease tracking
Monitor lesion counts and maximum diameters over time, with comparisons to baseline and prior timepoints
NeuroQuant® ARIA reports
Reports that assist in clinical decision-making by better characterizing ARIA, quantitating its occurrence, and assessing rate of change over time.
ARIA-H Report
NeuroQuant ARIA-H report provides automated microhemorrhage count and superficial siderosis area detection for patients receiving anti-amyloid therapies.
ARIA-E Report
NeuroQuant ARIA-E Report provides analysis and tracking of lesion count, max diameter, and volume for patients receiving anti-amyloid therapies.
